Humacyte Inc Stock Price, News & Analysis

Humacyte, Inc. (Nasdaq: HUMA) announced significant leadership changes, appointing Lt. General Bruce Green, M.D., USAF-ret., to its Board of Directors and Yang (Cindy) Cao, Ph.D., as Chief Regulatory Officer. Green's military medical background and Cao's extensive experience in drug development position the company well for advancing its Human Acellular Vessels™ (HAV™) technology towards regulatory approval. The HAV™ has shown promise in addressing vascular trauma and has received notable designations from the FDA, positioning Humacyte for critical advancements in regenerative medicine.

Humacyte has announced a clinical update on its Human Acellular Vessel (HAV) presented by Dr. Todd E. Rasmussen at the ICMM World Congress. The HAV aims to improve the treatment of vascular trauma, being infection-resistant and readily available for quick implantation. Over 500 patients have received HAV implants in ongoing clinical trials, which also include humanitarian efforts in Ukraine. The HAV has received FDA designations such as RMAT and Fast Track, indicating its potential in addressing vascular injury, especially in combat scenarios.

Humacyte, Inc. (Nasdaq: HUMA) announced an oral presentation of its Human Acellular Vessel (HAV) by Dr. Todd E. Rasmussen at the 44th ICMM World Congress, held in Brussels on September 7, 2022. The presentation focused on innovations for wartime vascular injuries. Additionally, Humacyte will participate in the HC Wainwright 24th Annual Global Investment Conference on September 14, 2022, in New York. The company continues to advance its acellular tissue technology aimed at treating various vascular conditions and has received multiple designations from the FDA for its HAV products.

Humacyte, a clinical-stage biotechnology company, reported second-quarter 2022 revenue of $1.3 million, up from $0.7 million in 2021. The company successfully implanted its Human Acellular Vessels™ in wounded Ukrainian citizens, reportedly saving limbs. Notable appointments were made to the Board, including Diane Seimetz as a new director and Shamik Parikh as Chief Medical Officer. Despite a net income of $36.9 million for the quarter, the company continues to spend heavily on R&D, totaling $14.7 million for the quarter, reflecting ongoing initiatives and preparations for a commercial launch.

Humacyte, Inc. (Nasdaq: HUMA) will release its financial results for Q2 2022 on August 12, 2022, during a conference call at 8:00 a.m. ET. The call will provide a corporate and financial update. Humacyte is focused on developing bioengineered human tissues for various medical applications, with its human acellular vessels (HAVs) in late-stage clinical trials targeting vascular applications. The HAV has received multiple FDA designations, including Regenerative Medicine Advanced Therapy and Fast Track.

Humacyte, Inc. (Nasdaq: HUMA) announced promising results from a preclinical study on its small-diameter Human Acellular Vessel (HAV) for coronary artery bypass grafting (CABG). Conducted in a non-human primate model, the HAV demonstrated structural integrity and patency for up to six months post-implantation, showcasing host cell remodeling. These findings were presented at the American Heart Association Basic Cardiovascular Sciences Scientific Sessions 2022. The HAV aims to address the limitations of saphenous vein grafts, frequently used in CABG procedures, potentially reducing risks associated with vein harvesting.

Humacyte, Inc. (Nasdaq: HUMA) announced the upcoming presentation of six-month outcomes from a preclinical study of its Human Acellular Vessel™ (HAV™) in coronary artery bypass grafting at the Basic Cardiovascular Sciences (BCVS) Scientific Sessions, scheduled for July 25-28, 2022, in Chicago, IL. The poster entitled 'Tissue-engineered Human Acellular Blood Vessels for Coronary Artery Bypass Grafting' will be presented by Dr. Adam Williams. Humacyte's HAVs are designed for vascular repair and have been used in nearly 500 patient implantations, highlighting their growing clinical significance.

Humacyte, Inc. (Nasdaq: HUMA) will host a KOL webinar on Human Acellular Vessels (HAV™) for vascular trauma on July 14, 2022. Esteemed speakers, Dr. Ernest E. Moore and Dr. Gregory A. Magee, will discuss the current treatment landscape and share patient case studies. HAV aims to provide off-the-shelf replacement vessels for vascular reconstruction, eliminating the need for internal harvesting and showing promise in clinical trials for being non-immunogenic and infection-resistant. More than 460 patient implantations have been conducted, with HAV currently in two Phase 3 trials.

Humacyte, Inc. (HUMA) reported significant advancements in its Human Acellular Vessel (HAV) for vascular treatments, with nearly 500 patients implanted and over 1,000 patient-years of follow-up. The HAV, designed to be durable and infection-resistant, is being evaluated in late-stage trials for arteriovenous access, peripheral arterial disease, and vascular trauma. Recent publications in JAMA Surgery and Annals of Vascular Surgery highlight its innovative nature and clinical efficacy, showcasing no infections or failures thus far. The HAV remains an investigational product and is not FDA-approved yet.